logo
States sue Trump, saying he is intimidating hospitals over gender-affirming care for youth

States sue Trump, saying he is intimidating hospitals over gender-affirming care for youth

Seventeen Democratic officials accused President Donald Trump's administration of unlawfully intimidating health care providers into stopping gender-affirming care for transgender youth in a lawsuit filed Friday.
The complaint comes after a month in which at least eight major hospitals and hospital systems — all in states where the care is allowed under state law — announced they were
stopping or restricting the care
. The latest announcement came Thursday from UI Health in Chicago.
Trump's administration announced in July that it was sending subpoenas to providers and focusing on investigating them for fraud. It later boasted in a news release that hospitals are halting treatments.
The Democratic officials say Trump's policies are an attempt to impose a nationwide ban on the treatment for people under 19 — and that's unlawful because there's no federal statute that bans providing the care to minors. The suit was filed by attorneys general from 15 states and the District of Columbia, plus the governor of Pennsylvania, in U.S. District Court in Boston.
'The federal government is running a cruel and targeted harassment campaign against providers who offer lawful, lifesaving care to children,' New York Attorney General Letitia James said in a statement.
Trump and others who oppose the care say that it makes permanent changes that people who receive it could come to regret — and maintain that it's being driven by questionable science.
Since 2021, 28 states with Republican-controlled legislatures have adopted policies to ban or restrict gender-affirming care for minors. In June, the U.S. Supreme Court ruled that states have a
right to enforce those laws
.
For families with transgender children, the state laws and medical center policy changes have sparked urgent scrambles for treatment.
The medical centers are responding to political and legal pressure
The Center for Transyouth Health and Development at Children's Hospital Los Angeles, the biggest public provider of gender-affirming care for children in teens in the U.S., closed in July.
At least seven other major hospitals and health systems have made similar announcements, including Children's National in Washington D.C., UChicago Medicine and Yale New Haven Health.
Kaiser Permanente, which operates in California and several other states, said it would pause gender-affirming surgeries for those under 19 as of the end of August, but would continue hormone therapy.
Connecticut Children's Medical Center cited 'an increasingly complex and evolving landscape' for winding down care.
Other hospitals, including Penn State, had already made similar decisions since Trump returned to office in January.
Alex Sheldon, executive director of GLMA, an organization that advocates for health care equity for LGBTQ+ people, said the health systems have pulled back the services for legal reasons, not medical ones.
'Not once has a hospital said they are ending care because it is not medically sound,' Sheldon said.
Trump's administration has targeted the care in multiple ways
Trump devoted a lot of attention to transgender people in his campaign last year as part of a growing pushback from conservatives as transgender people have gained visibility and acceptance on some fronts. Trump criticized gender-affirming care, transgender women in women's sports, and transgender women's use of women's facilities such as restrooms.
On his inauguration day in January, Trump signed an executive order defining the sexes as only male and female for government purposes, setting the tone for a cascade of actions that affect transgender people. About a week later, Trump called to stop using federal money, including from Medicaid, for gender-affirming care for those under 19.
About half of U.S. adults
approve of Trump's handling
of transgender issues, an AP-NORC poll found. But the American Medical Association says that
gender is on a spectrum
, and the group opposes policies that restrict access to gender-affirming health care.
Gender-affirming care includes a range of medical and mental health services to support a person's gender identity, including when it's different from the sex they were assigned at birth. It includes counseling and treatment with medications that block puberty, and hormone therapy to produce physical changes, as well as surgery, which is rare for minors.
In March, a judge paused enforcement of the ban on government spending for care.
The court ruling didn't stop other federal government action
In April, Attorney General Pam Bondi directed government investigators to focus on providers who continue to offer gender-affirming care for transgender youth. 'Under my leadership, the Department of Justice will bring these practices to an end,' she wrote.
In May, the Department of Health and Human Services issued a report
discouraging medical interventions
for transgender youth and instead focusing solely on talk therapy. The report questions adolescents' capacity to consent to life-changing treatments that could result in future infertility. The administration has not said who wrote the report, which has been deeply criticized by LGBTQ+ advocates.
In June, a Justice Department memo called for prioritizing civil investigations of those who provide the treatment.
In July, Justice Department announced it had sent more than 20 subpoenas to doctors and clinics involved in gender-affirming care for youth, saying they were part of investigations of health care fraud, false statements and other possible wrongdoing.
And in a statement last week, the White House celebrated decisions to end gender-affirming care, which it called a 'barbaric, pseudoscientific practice'
Families worry about accessing care
Kristen Salvatore's 15-year-old child started hormone therapy late last year at Penn State Health. Salvatore said in an interview with The Associated Press before the lawsuit was announced that it was a major factor in reduced signs of anxiety and depression. Last month, the family received official notice from the health system that it would no longer offer the hormones for patients under 19 after July 31, though talk therapy can continue.
Salvatore has been struggling to find a place that's not hours away from their Mechanicsburg, Pennsylvania, home that would provide the hormones and accept Medicaid coverage.
'I'm walking around blind with no guidance, and whatever breadcrumbs I was given are to a dead-end alleyway,' she said.
The family has enough testosterone stockpiled to last until January. But if they can't find a new provider by then, Salvatore's child could risk detransitioning, she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaccine opt-outs rise again among Arkansas kids
Vaccine opt-outs rise again among Arkansas kids

Axios

time3 minutes ago

  • Axios

Vaccine opt-outs rise again among Arkansas kids

The rate of nonmedical exemptions for vaccines among Arkansas kindergartners saw a slight uptick in the 2024-25 school year, according to newly released data from the CDC. The big picture: Vaccination coverage among American kindergartners decreased for all reported vaccines during the 2024-2025 school year. The drop coincides with measles cases hitting a 33-year high in the U.S., while Trump's Health Department secretary, Robert F. Kennedy Jr., upends longstanding vaccine norms. By the numbers: About 3.5% of kindergartners in Arkansas had nonmedical exemptions for vaccines in the 2024-25 school year, up from 3.4% the year before. The rate has continuously been trending upward. Just 1.2% of Arkansas kindergartners had a nonmedical exemption in the 2014-15 school year, according to the CDC. Medical exemptions in the state have held steady at about 0.1%, meaning 99.9% of children do not have a medical reason for not getting vaccinated. Threat level: Roughly 92-94% of the population needs to be vaccinated against measles to avoid community spread, according to the American Academy of Pediatrics.

Thursday briefing: Trump's tariffs; Fort Stewart shooting; Alzheimer's study; making potatoes healthy; and more
Thursday briefing: Trump's tariffs; Fort Stewart shooting; Alzheimer's study; making potatoes healthy; and more

Washington Post

timean hour ago

  • Washington Post

Thursday briefing: Trump's tariffs; Fort Stewart shooting; Alzheimer's study; making potatoes healthy; and more

President Donald Trump's new tariffs for dozens of countries took effect overnight. Tulsi Gabbard overrode CIA officials' concerns in a push to release a classified report. The U.S. plans to scale back its human rights criticisms of certain countries. Five soldiers were shot at Fort Stewart Army base in Georgia. Scientists found a potential key to reversing Alzheimer's disease.

Analysis-Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters
Analysis-Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

Yahoo

time2 hours ago

  • Yahoo

Analysis-Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some investors are betting that the beaten-down shares are now becoming too much of a bargain to pass up. The S&P 500 healthcare sector -- which includes pharmaceutical companies, biotechs, health insurers and medical equipment makers -- has slumped 5% in 2025, lagging the over 7% gain for the overall index. Pressure to bring down U.S. prescription drug prices to overseas rates, tariffs targeted at pharmaceuticals and cuts to areas such as health research funding and Medicaid are among the Trump administration actions clouding the outlook for the shares this year, investors said. Regulatory obstacles are compounding issues, including expiring drug patents and setbacks for bellwethers including UnitedHealth Group. "You have got this constant overarching political and regulatory overhang that doesn't really seem to subside with any administration," said Jared Holz, healthcare sector strategist at Mizuho Securities. "When you have so much nebulousness around the sector, it turns people off rather than invites them to the party." In another sign of the group losing favor, healthcare exchange-traded-funds have seen 12 consecutive months of net outflows as of July for a total outflow of $11.5 billion in that time, more than for any other sector, according to State Street Investment Management. The performance picture is even dimmer over a longer period. While shares of massive technology companies pushed the benchmark S&P 500 up over 50% the past three years, the healthcare sector is little changed in that time. That gap has put the 60-stock sector at nearly its biggest discount to the broader market in 30 years, which some investors hope is an inflection point for the battered group. "The valuation is extremely cheap and the relative performance is at an extreme," said Walter Todd, chief investment officer at Greenwood Capital, whose healthcare holdings include diversified giant Johnson & Johnson and medical device maker Stryker. "So at this point, it seems like a pretty decent setup to get some outperformance." The price-to-earnings ratio for the healthcare sector, based on earnings estimates for the next year, has fallen to 16.2 times from nearly 20 a year ago, according to LSEG Datastream. Meanwhile, the S&P 500's rally to records has driven the index's P/E ratio to over 22 times -- giving the broader market a significant premium over the healthcare sector. 'BAD NEWS IS PRICED IN' Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, against its long-term average of 14.5, while fellow drugmaker Bristol Myers Squibb trades at 7.4 against its average of 15.8, according to LSEG. Year-to-date, shares of both Merck and Bristol Myers are down roughly 20%. The group is drawing bets from some value investors such as Patrick Kaser, portfolio manager at Brandywine Global, whose portfolio is overweight the sector including owning shares of CVS Health and European drugmakers GSK and Sanofi. "Our perspective is a lot of this bad news is priced in and then some," Kaser said. "To bet against the sector from here, you're essentially continuing to bet on the valuation gap, which is already large, continuing to widen." The group's decline means the total market value of the S&P 500 healthcare sector is about $4.8 trillion, not much higher than the $4.3 trillion value of Nvidia, the semiconductor company that has symbolized the artificial intelligence boom. Indeed, some investors said a shift in capital away from Nvidia and other massive tech companies could spark healthcare shares. Such a move appeared to occur in the first quarter, investors said, when the healthcare sector rose 6% while declines in tech and megacap stocks dragged indexes lower. Fears of an economic downturn also could help healthcare shares, at least on a relative basis. The group is often viewed as a defensive area in rockier economic times. Economic fears flared following last Friday's weaker-than-expected employment report, while some strategists say the market could be due for a pullback after surging over 20% since its April lows. "During the first quarter, healthcare did great even as tech rolled over, as the fears of an economic slowdown got to more economically sensitive stocks," said Chris Grisanti, chief market strategist at MAI Capital Management, adding he expects healthcare "will perform better in a more difficult market." More clarity on regulatory issues, including tariffs, also could support healthcare, investors said. But some value investors are hesitant to dive into the group. Michael Mullaney, director of global markets research at Boston Partners, said he is wary some healthcare shares could be "value traps," preferring to overweight areas including industrials or financials. "There's been just so much of an overhang in the sector," Mullaney said. "There are better places to go with cleaner stories." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store